Skip to main content

Catalyst Calendar

Scope

Thu, Oct 1, 2026

1 updates
HRMY
8:05 AM

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia.

Presentation / Abstract • Phase 3Poster presentation Fri, Oct 2, 2026, 4:30 PM CESTharmonybiosciences.com

Tue, Sep 22, 2026

1 updates

Thu, Sep 3, 2026

1 updates
HRMY
8:05 AM

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16 th European Epilepsy Congress being held from September 5-9,

Presentation / AbstractPoster presentation Sun, Sep 6, 2026, 2:00 PM EESTharmonybiosciences.com

Thu, Aug 27, 2026

1 updates
HRMY
8:05 AM

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20

harmonybiosciences.com

Thu, Aug 6, 2026

1 updates
HRMY
8:05 AM

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

harmonybiosciences.com

Tue, Aug 4, 2026

1 updates
HRMY
7:30 AM

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles;

Interim Data • Phase 1Initial Phase 1 SAD data release Tue, Aug 4, 2026, 8:30 AM ETharmonybiosciences.com

Tue, Jul 21, 2026

1 updates

Thu, Jul 16, 2026

1 updates